期刊
MOLECULAR THERAPY
卷 24, 期 1, 页码 6-16出版社
CELL PRESS
DOI: 10.1038/mt.2015.194
关键词
-
资金
- Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences
- British Heart Foundation Chair of Translational Cardiovascular Sciences
- Framework 7 Industry Academy Partnership Programme AD-VEC [324325]
- BBSRC [BB/L027933/1, BB/L027933/2] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/L027933/2, BB/L027933/1] Funding Source: researchfish
Recombinant vectors based on human adenovirus serotype 5 (HAdV-5) have been extensively studied in preclinical models and clinical trials over the past two decades. However, the thorough understanding of the HAdV-5 interaction with human subjects has uncovered major concerns about its product applicability. High vector-associated toxicity and widespread preexisting immunity have been shown to significantly impede the effectiveness of HAdV-5-mediated gene transfer. It is therefore that the in-depth knowledge attained working on HAdV-5 is currently being used to develop alternative vectors. Here, we provide a comprehensive overview of data obtained in recent years disqualifying the HAdV-5 vector for systemic gene delivery as well as novel strategies being pursued to overcome the limitations observed with particular emphasis on the ongoing vectorization efforts to obtain vectors based on alternative serotypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据